Universal donor immune cells

One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells. This therapy, currently tested in early clinical trials for melanoma and neuroblastoma, has its limitations: Removing immune cells from a patient and growing them outside the body for future re-injection is extremely expensive and not always technically feasible.

Weizmann Institute scientists have now tested in mice a new form of adoptive cell transfer, which overcomes these limitations while enhancing the tumor-fighting ability of the transferred cells. The research, reported recently in Blood, was performed in the lab of Prof. Zelig Eshhar of the Institute's Immunology Department, by graduate student Assaf Marcus and lab technician Tova Waks.

The new approach should be more readily applicable than existing adoptive cell transfer treatments because it relies on a donor pool of immune T cells that can be prepared in advance, rather than on the patient's own cells. Moreover, using a method pioneered by Prof. Eshhar more than two decades ago, these T cells are outfitted with that specifically seek out and identify the tumor, thereby promoting its destruction.

In the study, the scientists first suppressed the of mice with a relatively mild dose of radiation. They then administered a controlled dose of the modified donor T cells. The mild suppression temporarily prevented the donor T cells from being rejected by the recipient, but it didn't prevent the cells themselves from attacking the recipient's body, particularly the tumor. This approach was precisely what rendered the therapy so effective: The delay in the rejection of the donor T cells gave these cells sufficient opportunity to destroy the tumor.

If this method works in humans as well as it did in mice, it could lead to an affordable cell transfer therapy for a wide variety of cancers. Such therapy would rely on an off-the-shelf pool of donor equipped with receptors for zeroing in on different types of cancerous cells.

add to favorites email to friend print save as pdf

Related Stories

Scientists create new cloning method

Oct 04, 2006

U.S. scientists say they have achieved a one-step somatic cell nuclear transfer procedure using a differentiated cell as a nuclear donor.

Stem cell breakthrough: Bone marrow cells are the answer

Jan 28, 2010

Using cells from mice, scientists from Iowa and Iran have discovered a new strategy for making embryonic stem cell transplants less likely to be rejected by a recipient's immune system. This strategy, described in a new research ...

Drug/radiation combo may help shrink established tumors

Aug 25, 2008

Researchers may be closer to understanding why anti-cancer drugs such as Ipilimumab, which boost the tumor-killing power of immune cells, haven't fared well in clinical trials. The new study, which describes a way to enhance ...

Recommended for you

Hydrogen sulfide could help lower blood pressure

56 minutes ago

A gas that gives rotten eggs their distinctive odour could one day form the basis of new cardiovascular therapies. Research has indicated that a new compound, called AP39, which generates minute quantities ...

Researchers design tailored tissue adhesives

5 hours ago

After undergoing surgery to remove diseased sections of the colon, up to 30 percent of patients experience leakage from their sutures, which can cause life-threatening complications.

New cells may help treat diabetes

20 hours ago

Starting from human skin cells, researchers at the University of Iowa have created human insulin-producing cells that respond to glucose and correct blood-sugar levels in diabetic mice. The findings may represent ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.